Pharmaceutical Benefit Plan Settlements

Updated: 5 days ago

$439 Million available via Pharmaceutical Benefit Plan Settlements

Overview

There are typically several active lawsuits and/or class action settlements that fall into the category of “pharmaceutical benefit plan settlements.” Under these cases, it is generally alleged that businesses with self-insured health plans overpaid for drugs purchased on behalf of their employees due to artificially inflated and/or stabilized prices.


The prices were allegedly manipulated as a result of anti-competitive practices undertaken by the drug manufacturers. The number of these opportunities in any given year varies, but there can be several available at the same time.


Immediately Available Settlement(s):


Settlement Name: EpiPen (Branded & Generic) Antitrust Litigation-Mylan Settlement*

Product(s): Branded EpiPens/Authorized Generic EpiPens

Date Range: Aug. 2011 - Nov. 2020

Settlement Fund: $264 Million ($211,200,000 for Benefit Plans)

Filing Deadline: 7/25/2022


PLEASE NOTE: THE FILING DEADLINE TO SUBMIT A CLAIM TO THIS SETTLEMENT HAS PASSED. MCAG WILL UPDATE CLIENTS ACCORDINGLY ONCE INFORMATION IS AVAILABLE ON DISTRIBUTIONS FROM THIS SETTLEMENT.


Settlement Overview: Under this settlement, it is alleged that defendants violated federal antitrust laws as well as the federal Racketeer Influenced and Corrupt Organizations (“RICO”) Act, causing both consumers and businesses with self-insured health plans to pay supracompetitive prices for the branded EpiPen (a spring-loaded injector that delivers a pre-measured and pre-loaded amount of epinephrine for emergency treatment of anaphylaxis) and authorized generic EpiPens. Pfizer settled end-payor claims in 2021, this settlement resolves litigation against remaining defendant-Mylan.


Eligible Locations: All organizations located within the United States.

*If you were an eligible class member and a client with MCAG before November 11, 2021, that provided supporting data for your claim, you do not need to do anything. You will automatically be included as a class member of the settlement with Mylan.

If you believe your organization is an eligible class member and you were either not a client with MCAG for the Pfizer EpiPen Settlement or your organization has not provided supporting data, please reach out to an MCAG customer service representative for assistance to complete your claim.


Settlement Name: Restasis Settlement

Date Range: May 2015 - July 2021

Settlement Fund: $29,999,999.99 ($25,020,000 for Benefit Plans)

Filing Deadline: 8/11/2022


PLEASE NOTE: THE FILING DEADLINE TO SUBMIT A CLAIM TO THIS SETTLEMENT HAS PASSED. MCAG WILL UPDATE CLIENTS ACCORDINGLY ONCE INFORMATION IS AVAILABLE ON DISTRIBUTIONS FROM THIS SETTLEMENT.


Settlement Overview: This settlement resolves allegations that Defendant Allergan kept generic versions of Restasis, a medication used to treat chronic dry eye syndrome, off the market which made Restasis prices higher than they otherwise would have been.


Eligible Locations: To be a member of the Settlement Class, you must have paid and/or provided reimbursement for some or all of the purchase price of Restasis that was purchased either in a pharmacy or received by mail-order prescription, in any of the eligible states and territories below:

  • Arizona, Arkansas**,California, Colorado, the District of Columbia, Florida, Hawaii, Illinois, Iowa, Kansas, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, Rhode Island, South Dakota, Tennessee, Utah, West Virginia, and Wisconsin.

**Arkansas purchases, payments, and reimbursements for Restasis must have occurred between May 1, 2015 and July 31, 2017.


Eligible Drug (s): Restasis


Settlement Name: Ranbaxy Settlement

Date Range: Sept. 2012 - April 2020

Settlement Fund: $145 Million (for Benefit Plans)

Filing Deadline: 10/11/2022

Settlement Overview: This settlement resolves allegations that Defendant Ranbaxy manipulated the U.S. Food and Drug Administration’s generic-drug approval process, limiting competition and violating antitrust laws. A fund has been created for third party payors, covering three drugs: antiviral drug Valcyte, high blood pressure drug Diovan, and reflux medication Nexium.

Eligible Locations: All organizations located within the United States.


Eligible Drug (s): Brand/Generic Diovan, Brand/Generic Valycte, Generic Nexium

 

Recommended Next Steps Data is often required to complete your claim for settlements in this category. Connect us with a member of your Benefits Department so an MCAG representative can describe the information that is necessary to complete your claim for these pharmaceutical settlements. We typically only need a 5 to 10 minute call. We will quickly review the process so we can efficiently obtain necessary information from your Pharmacy Benefit Manager (i.e. CVS Caremark, Express Scripts, OptumRX) to pursue current and future pharmaceutical settlements.


Eligible contracted clients can expect to be contacted by an MCAG representative to review and assist with gathering all of the necessary information for these settlements.


MCAG is not the Settlement/Class Administrator, and this is not an official settlement website.


Need more information? CLICK HERE to complete our contact form and an MCAG representative will respond shortly.